Azar Shahraz

A moderated panel drawing on speakers from across both conference days to share honest retrospective experience of MIDD implementation.

• Where has MIDD genuinely changed a development decision, and where has it been used to validate a decision that had already been made?
• What has been the hardest internal sell for MIDD, and what argument finally worked?
• Where have you seen the field overclaim what modelling can do, and what are the consequences of that for regulatory trust?

• The practical challenge of communicating model outputs, assumptions, and uncertainty to cross-functional colleagues and senior leaders who need to make decisions based on those outputs without a pharmacometrics background
• Frameworks for presenting model credibility to internal stakeholders, including how to communicate what the model can and cannot tell you without undermining confidence in the work
• Case examples where poor internal communication of MIDD results delayed a development decision, and what changed when the communication approach was redesigned